Navigation Links
Aussie neuroscientist tests addiction drug
Date:2/19/2008

UQ pharmacy graduate Dr Selena Bartlett is starting clinical trials of a new drug that could potentially curb addictions such as smoking, drinking, gambling even depression.

The drug, marketed as Chantix by Pfizer, has reduced alcohol consumption in laboratory rats by 50 percent and will be trialled in humans next month by Dr Bartlett and Dr Markus Heilig's team in the United States.

Chantix latches onto good feeling' receptors in the brain to block cravings for addictions such as nicotine or alcohol.

Dr Bartlett is the Director of the Preclinical Development Group at the Ernest Gallo Clinic and Research Centre, one of the world's top alcohol and addiction research centres, at the University of California in San Francisco.

She said she was convinced of the drug's potential but it had been hard to convince others, despite the drug gaining widespread media attention in the US.

Big companies still do not believe in the potential of addiction as a market, believe it or not, Dr Bartlett said.

The Chantix trials are just one of 10 major projects for Dr Bartlett's lab team, which is working on reducing ethanol consumption and new drug screening technologies.

Dr Bartlett was asked to set up her preclinical lab to study addiction and how it modifies brain function.

I wanted to make a difference in the world and develop treatments that would help people, she said.

Addiction is currently one of the most under-served and least understood.

Her passion for understanding brain functions stemmed from her late-sister who had schizophrenia.

She is still very much a driving force in my life and the reason I am doing this type of translational research.

She also hopes to create a Foundation to fund research and develop better treatments for neuropsychiatric diseases such as schizophrenia, in memory of her sister.

Dr Bartlett grew up in the small South Burnett town of Nanango, where her parents ran the local pharmacy for 35 years until last November.

She went to UQ like many of her siblings, parents and her husband's parents and grandparents going back to the 1920s.

She studied pharmacy at UQ with a Bachelor, Hons and PhD by 1994, with the expectation that she eventually work back in the family pharmacy.

By the time she finished her pharmacy study with a focus on morphine tolerance and dependence, she had also found two loves her husband and neuroscience.

I loved my time at UQ. It changed my life. I went in with all intentions of becoming a practising pharmacist and left a neuroscientist.

I became addicted to the thrill of a new discovery and research . . .I also fell in love with neurosciences.

I could see that understanding the neurobiological basis of addiction would provide valuable insights into brain function but also would help to uncover the causes of this devastating disease.

Dr Bartlett and her husband Peter, also a UQ student at the time studying electrical engineering and computer science, met while windsurfing at the Gold Coast.

After working in Australia they moved to the US and then Dr Bartlett was offered the job of setting up a lab to develop a new model of translational research.

I was advised not to do it. This is where being Australian and my early experiences in Nanango really kicked in. I decided to give it a go.

She said growing up in a small country town and her time in the family's pharmacy gave her a pioneering attitude, fearlessness and stubbornness.

I remember counting pills the old way, one by one, or ten by ten.

I have vivid memories of my dad making ointments on a glass slab.

My dad used to make industrial quantities of ointments at one time. The ointment was gooey and took forever to make, sometimes hours.


'/>"/>

Contact: Miguel Holland
m.holland@uq.edu.au
61-733-652-619
Research Australia
Source:Eurekalert

Related medicine news :

1. Brandeis neuroscientist wins NIH directors Pioneer Award
2. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
3. Leading neuroscientist seeks beauty, love and happiness
4. Carnegie Mellon neuroscientist proposes new theory of brain flexibility
5. Jefferson neuroscientists find early lead exposure impedes recovery from brain injury
6. MITs McGovern Institute honors Emory neuroscientist for contributions to psychiatry
7. Experts propose cholesterol tests at 15 months of age
8. Fecal Blood Tests Effective at Spotting Colon Cancer
9. Drug Industry Seeks Tests to Spot Side Effect Risks
10. Noninvasive tests for cirrhosis may help to avoid liver biopsy
11. K-State Veterinary Lab Routinely Tests For Bluetongue Virus; Lab Director Says Strains Found in Kansas, U.S. Usually Less-Virulent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/28/2016)... ... ... of the city where’s it’s easy to spot the neon lights of chains serving fast ... diners with a taste for real food. , On May 13, the Best ... urban casual restaurant focusing on dishes made by hand with wholesome, organic ingredients that are ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Hutchison China ... focused on the highly lucrative global oncology and ... of potential first-in-class or best-in-class tyrosine kinase inhibitor ... with strategic partners. HCM,s profitable Chinese healthcare business ... We expect progress of the mid-to-late-stage pipeline during ...
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology: